Finerenone

非奈利酮

Report date: 2026/05/21 20:00:22
NMEFirst In Class

Base Information

Drug NameFinerenone
Drug Alias NameKerendia可申达KERENDIAFirialtaBAY-94-8862
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor antagonists
TargetsMineralocorticoid receptor
Therapy Area/IndicationsRejection of renal transplantationDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[18] 
Global Approved IndicationsDiabetes Mellitus, Type 2Myocardial InfarctionHeart Failure +[7] 
Approved Indications in ChinaRenal Insufficiency, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2021/07/09
Country/TerritoryCzechiaBelgiumBulgaria +[56] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenOregon Health And Science UniversityUniversity Of Erlangen-Nuremberg Medical School +[11] 
Inactive CompaniesBayer Pharma AgBayer HealthCare AG
Active IndicationsRejection of renal transplantationDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[17] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG